Liquid Biopsy Company, Exact Sciences: Non-Invasive Cancer Screening and Multi-Cancer Pipeline

Services & Portfolio

Exact Sciences (NASDAQ: EXAS) has become synonymous with non-invasive cancer screening, spearheaded by its flagship product Cologuard. Approved by the FDA in 2014, Cologuard is the first stool-based DNA test that detects colorectal cancer (CRC) and precancerous polyps by analyzing:

  • DNA mutations
  • Methylation markers
  • Fecal blood markers

Cologuard addresses a critical need for non-invasive early cancer detection, offering an alternative to colonoscopy for average-risk adults.

Expansion into Liquid Biopsy

Building on Cologuard’s success, Exact is actively developing blood-based liquid biopsy tests, including:

  • A Multi-Cancer Early Detection (MCED) blood test
  • A next-generation blood-based CRC screening test

Exact’s MCED pipeline combines circulating DNA methylation patterns and protein biomarkers, allowing detection of multiple cancers from a single blood draw.

Precision Oncology Offerings

Exact Sciences expanded into precision oncology through acquisitions:

  • Oncotype DX genomic tests (tissue-based) for prognosis in breast and colon cancer

Despite this, Exact’s core focus remains on early cancer detection in asymptomatic populations, distinguishing it from competitors that emphasize tumor profiling for treatment decisions.

Proof of Concept & Validation

Exact’s credibility in early detection is anchored in Cologuard’s pivotal trial:

  • 92% sensitivity for colorectal cancer
  • 42% sensitivity for advanced pre-cancerous polyps
  • 87% specificity

Over 10 million Cologuard tests have been performed, significantly increasing early-stage CRC detection rates.

In 2023, Exact presented promising MCED results from a 20,000-subject prospective study:

  • 50.9% overall sensitivity at 98.5% specificity across 21 cancer types
  • Higher sensitivity (~63.7%) in deadliest cancers (lung, ovarian, pancreatic)

However, commercialization is being moderated pending Medicare reimbursement authorization. Exact is actively supporting the MCED Coverage Act in Congress to address this barrier.

Meanwhile, the BLUE-C study, evaluating a blood-based CRC screening test, reported:

  • ~90% sensitivity for CRC
  • 92% specificity

Revenue, Market Share & Niche

In 2023:

  • Exact Sciences generated $1.8 billion in screening revenue, primarily from Cologuard—up 31% from 2022
  • Over 3.7 million Cologuard tests were completed
  • Including precision oncology (Oncotype DX), total revenues exceeded $2.0 billion

Market Penetration

Exact holds a strong position in colorectal screening, competing directly with colonoscopies and FIT:

  • The ~20-30 million Americans not up-to-date on CRC screening represent a significant growth opportunity
  • Cologuard is now a standard guideline option, listed alongside colonoscopy and FIT

Competitive Landscape

  • Guardant Health’s Shield test received FDA approval in 2024, intensifying competition in blood-based CRC screening
  • In MCED, Exact is racing against Grail (Galleri), Freenome, and others

Despite being slightly behind in MCED development, Exact’s extensive primary care network and existing commercial success provide the resources to catch up quickly

Technology & Differentiation

Exact Sciences distinguishes itself through:

  • A multi-marker strategy integrating cfDNA methylation analysis and protein biomarkers
  • Cost-effective assays, potentially cheaper than Grail’s sequencing-heavy Galleri test

Key technological assets include:

  • Massive sample database (from Cologuard) for biomarker discovery
  • Machine learning to refine marker selection
  • Acquired IP from Thrive (CancerSEEK test) and Base Genomics (methylation technology)

Operational Strength

Exact’s high-throughput clinical labs, nationwide payer coverage, and physician outreach offer a significant competitive edge. The company can:

  • Bundle screening offerings
  • Negotiate reimbursement with real-world evidence of cost savings from early detection

Ultimate Aims

Exact Sciences' mission:
“Eradicate cancer and the suffering it causes through tests that help detect cancer earlier or guide treatment.”

Strategic objectives include:

  • 40% market share in CRC screening (currently ~10%)
  • FDA approval for its MCED blood test, contingent on clinical data and reimbursement readiness
  • Expansion into liver cancer screening (via partnership with HelioLiver)
  • Development of minimal residual disease (MRD) tests and therapy selection tools in precision oncology

Market Expansion

Exact aims to scale from tens of millions to hundreds of millions of people globally:

  • Potential bundling of multi-cancer early detection (MCED) with single-cancer tests
  • Focus on workflow simplification, including potential at-home blood collection

Conclusion

Exact Sciences is leveraging its proven track record, commercial strength, and R&D innovation to lead the next wave in non-invasive cancer screening. With Cologuard, it transformed CRC screening. Now, it’s setting its sights on multi-cancer detection, liquid biopsy leadership, and global market expansion.

Resources & References

  1. MedCity News. "Exact Sciences Builds on Cologuard Success with New Blood-Based Tests."
    https://medcitynews.com/2023/10/exact-sciences-builds-on-cologuard-success-with-new-blood-based-tests

  2. MedTech Dive. "Exact Sciences’ MCED Blood Test Shows Promise in Large Study."
    https://www.medtechdive.com/news/exact-sciences-mced-blood-test-study/639951

  3. US Preventive Services Task Force. "Screening for Colorectal Cancer Recommendation Statement."
    https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening

  4. American Cancer Society (ACS) Annual Meeting 2022 Abstracts.
    https://www.abstractsonline.com/pp8/#!/10517

  5. Fierce Biotech. "Grail’s Galleri and the Race for Multi-Cancer Early Detection."
    https://www.fiercebiotech.com/medtech/grail-s-galleri-and-race-multi-cancer-early-detection

  6. U.S. Congress. "MCED Coverage Act (H.R. 2407)."
    https://www.congress.gov/bill/118th-congress/house-bill/2407

  7. Exact Sciences Investor Presentation Q4 2023.
    https://exactsci-files.s3.us-west-2.amazonaws.com/investor-relations/2023-Q4-Investor-Presentation.pdf

  8. Helio Genomics and Exact Sciences Partnership Announcement.
    https://www.heliogenomics.com/news/exact-sciences-and-helio-partner-on-liver-cancer-screening

  9. Thrive Earlier Detection Acquisition by Exact Sciences.
    https://www.exactsciences.com/newsroom/thrive-acquisition

  10. Guardant Health News. "FDA Approves Shield Blood Test for Colorectal Cancer Screening."
    https://www.guardanthealth.com/fda-approves-shield-blood-test-for-crc-screening

If you’d like to customize this further or add more technical detail, just let me know!

Comments

Post a Comment

Popular posts from this blog

2025 JPM Healthcare Conference: 0. The Revival of M&A in the Healthcare Industry

  A New Era for M&A Market One of the hottest topics at the 2025 JPM Healthcare Conference was the resurgence of mergers and acquisitions (M&A) in the healthcare sector . With the second Trump administration expected to bring deregulation and corporate tax cuts , major pharmaceutical and biotech companies are aggressively pursuing M&A strategies once again. This acceleration is driven by rising drug development costs, the need for pipeline expansion, and global market expansion efforts. Why M&A is Gaining Momentum 1. Deregulation and Increasing Market Competition The Trump administration is anticipated to implement more business-friendly policies , including antitrust regulation relaxation and reduced drug price controls . These factors will likely encourage large pharmaceutical companies to actively acquire smaller biotech firms. 2. The Race to Secure Blockbuster Drugs The competition for GLP-1 class diabetes and obesity treatments and other innovative drugs is ...
Read more

JPM2025 Healthcare Conference: 4. Digital health and Digital Therapeutics

  The Role of Digital Health and Digital Therapeutics in Healthcare: Insights from JPM2025 AI Integration in Healthcare Artificial Intelligence (AI) continues to reshape healthcare delivery, with JPM2025 showcasing some of the most promising AI-driven solutions. NVIDIA’s Collaborations: The tech giant has partnered with Mayo Clinic, IQVIA, Arc Institute, and Illumina to accelerate AI applications in drug discovery and personalized medicine. These collaborations aim to enhance real-time healthcare decision-making and improve patient outcomes ( Meet Life Sciences ). AI in Diagnostics and Remote Monitoring: Startups are leveraging AI to improve disease detection and continuous patient monitoring, reducing hospital readmissions and optimizing clinical workflows. Cross-Industry Collaborations Driving Digital Health Technology and healthcare companies are joining forces to bring digital health solutions to a broader audience. Teladoc Health & Amazon’s Health Benefits Conn...
Read more

TSMC's $100 Billion U.S. Investment Under Trump's Second Administration: A Game-Changer for the Semiconductor Industry (Business Section)

1. Introduction   Taiwan Semiconductor Manufacturing Company (TSMC), the world's leading contract chip manufacturer, has announced a $100 billion investment to expand its semiconductor manufacturing operations in the United States. This decision comes as part of the Trump administration's strategic push to bolster domestic chip production and reduce reliance on foreign supply chains. The expansion, set to take place in Arizona, will significantly impact the global semiconductor landscape, strengthening U.S. technological self-reliance and national security. 2. Summary of the Deal   On March 3, 2025, TSMC CEO C.C. Wei met with President Donald Trump to unveil plans for the construction of five new fabrication plants in Arizona. This investment supplements TSMC's previous $65 billion commitment in the state. The expansion aims to manufacture cutting-edge semiconductor chips crucial for artificial intelligence (AI), defense, and high-performance computing applications. 3. Stra...
Read more